|
19 Aug 2023 |
BITT Announces FDA Acceptance of IND for TNFR2 Antibody
|
|
19 Aug 2023 |
EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for Treatment of Wet Age-related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)
|
|
19 Aug 2023 |
Veopoz™ (pozelimab-bbfg) Receives FDA Approval as the First Treatment for Children and Adults with CHAPLE Disease
|
|
19 Aug 2023 |
Fibroblast Activation Protein (FA): an ideal tumor stroma target for payload delivery
|
|
18 Aug 2023 |
Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific
|
|
18 Aug 2023 |
Akeso Announced First Patient Dosed in Phase 3 Trial of Ivonescimab versus Tislelizumab for First-line Treatment of Squamous NSCLC
|
|
18 Aug 2023 |
Inmagene's anti-OX40 mAb demonstrated an extended half-life and a favorable safety profile in a Phase I study
|
|
18 Aug 2023 |
Odronextamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
|
|
18 Aug 2023 |
European Commission Approves Reduced Dosing Frequency for Janssen’s Bispecific Antibody TECVAYLI (teclistamab)
|
|
18 Aug 2023 |
NextPoint Therapeutics Announces First Patient Dosed in Phase 1a/b Clinical Trial of NPX267, a Novel Therapeutic Targeting KIR3DL3 to Reactivate Exhausted T and NK Cells in HHLA2+ Solid Tumors
|
|
17 Aug 2023 |
Folate Receptor alpha: a validated target for application of novel drug modalities
|
|
17 Aug 2023 |
Tonix Pharmaceuticals Initiates Phase 1 Trial of TNX-1500 (Fc-modified humanized anti-CD40L mAb) in Healthy Volunteers
|
|
17 Aug 2023 |
Elevation Oncology Announces First Patient Dosed in the Phase 1 Clinical Trial Evaluating EO-3021
|
|
17 Aug 2023 |
Innovent Announces the NMPA Approval of SINTBILO® (Tafolecimab Injection) for the Treatment of Adult Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia
|
|
16 Aug 2023 |
Tiziana Life Sciences Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimer’s Disease
|
|
16 Aug 2023 |
Novel biologic Ab-IPL-IL-17™ shows promise for rheumatoid arthritis and inflammatory bowel disease
|
|
16 Aug 2023 |
OnCusp Therapeutics Receives FDA Clearance for the Phase 1 Clinical Trial of CUSP06, Targeting Ovarian Cancer and Other Advanced Solid Tumors
|
|
16 Aug 2023 |
Inmagene's OX40 mAb, with an extended half-life and silenced ADCC, enters POC study in Atopic Dermatitis
|
|
15 Aug 2023 |
IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review
|
|
15 Aug 2023 |
Pfizer’s ELREXFIO™ Receives U.S. FDA Accelerated Approval for Relapsed or Refractory Multiple Myeloma
|
|
15 Aug 2023 |
Sandoz announces positive results from Mylight Phase lll study for biosimilar aflibercept
|
|
12 Aug 2023 |
Zumutor Biologics Inc announces FDA clearance of IND application of ZM008, a novel monoclonal antibody drug against multiple solid cancers
|
|
12 Aug 2023 |
Bio-Thera Solutions Announces Positive Phase 1 Clinical Data for BAT8006 (Folate-Receptor-α-ADC) and Presents Phase 1 Dose Escalation Study at the Bethune Obstetrics and Gynecology Forum
|
|
11 Aug 2023 |
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
|
|
11 Aug 2023 |
Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors
|
